Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
AIDS Behav ; 28(3): 868-885, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37831233

ABSTRACT

Human immunodeficiency virus (HIV) viral load (VL) monitoring was likely interrupted during the Coronavirus disease 2019 (COVID-19) pandemic. We used routine data on repeat VL testing among 667 prevention of vertical HIV transmission (PVT) clients in Ehlanzeni district, to determine compliance to VL testing recommendations and associated factors during different time periods: pre-COVID-19, transition, and COVID-19. Descriptive and multivariable Poisson regression analyses were conducted, with and without including revised PVT-guidelines rolled out in January-2020. Among 405 women with ≥ 2 VL tests, the overall median age was 30 years (interquartile range: 26-35 years). Compliance to recommended VL testing guidelines ranged between 81.5% (172/211) and 92.3% (191/207) at different time periods. Across all three periods and when revised PVT-guidelines were used, being compliant was significantly reduced among those with earliest VL = 50-999 copies/ml (incidence rate ratio (IRR) = 0.71 [95% confidence interval (CI) 0.61-0.82], p value < 0.001) and VL ≥ 1000 copies/ml (IRR = 0.18 [95% CI 0.09-0.36], p value < 0.001). When guideline revisions were excluded, compliance was only significantly reduced among those with VL ≥ 1000 copies/ml (IRR = 0.14 [95% CI 0.06-0.32], p value < 0.001) and increased during the COVID-19 period versus pre-COVID-19 (IRR = 1.10 [95% CI 1.05-1.15], p value < 0.001). Similar significant associations between compliance and VL level were observed when the COVID-19 period was analyzed separately. Significantly increased compliance to VL testing among the 25-34 years age-group versus younger women was also observed across all periods. These results highlight the importance of strengthening strategies such as short message service reminders and educational messaging, reaching all age-groups, to fast-track implementation targets for VL monitoring.


Subject(s)
Anti-HIV Agents , COVID-19 , HIV Infections , Humans , Female , Adult , HIV Infections/epidemiology , HIV Infections/prevention & control , HIV Infections/drug therapy , Pandemics/prevention & control , Viral Load , South Africa/epidemiology , COVID-19/epidemiology , COVID-19/prevention & control , Anti-HIV Agents/therapeutic use
2.
S Afr Med J ; 102(3 Pt 1): 171-5, 2012 Feb 23.
Article in English | MEDLINE | ID: mdl-22380915

ABSTRACT

Prepared on behalf of the South African Society of Thombosis and Haemostasis. Background. Recent progress has been made in the understanding of venous thrombo-embolism (VTE) in children and neonates; however, indications for laboratory investigations and therapeutic interventions are not well defined. Method. The Southern African Society of Thrombosis and Haemostasis reviewed available literature and comprehensive evidence-based guidelines for paediatric antithrombotic therapy. A draft document was produced and revised by consensus agreement. The guidelines were adjudicated by independent international experts to avoid local bias. Results and conclusion. We present concise, practical guidelines for the clinical management and laboratory investigation of VTE in children and neonates. Recommendations reflect current best practice which will hopefully lead to improved anticoagulation practice in this age group.


Subject(s)
Anticoagulants , Drug Monitoring/methods , Venous Thromboembolism , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Blood Coagulation/drug effects , Child , Disease Management , Hemorrhage/chemically induced , Hemorrhage/therapy , Humans , Infant , Venous Thromboembolism/diagnosis , Venous Thromboembolism/drug therapy , Venous Thromboembolism/etiology , Venous Thromboembolism/physiopathology , Warfarin/administration & dosage , Warfarin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...